Epidemiology of peritoneal dialysis outcomes.
Nat Rev Nephrol
; 18(12): 779-793, 2022 12.
Article
in English
| MEDLINE | ID: covidwho-2036833
ABSTRACT
Peritoneal dialysis (PD) is an important home-based treatment for kidney failure and accounts for 11% of all dialysis and 9% of all kidney replacement therapy globally. Although PD is available in 81% of countries, this provision ranges from 96% in high-income countries to 32% in low-income countries. Compared with haemodialysis, PD has numerous potential advantages, including a simpler technique, greater feasibility of use in remote communities, generally lower cost, lesser need for trained staff, fewer management challenges during natural disasters, possibly better survival in the first few years, greater ability to travel, fewer dietary restrictions, better preservation of residual kidney function, greater treatment satisfaction, better quality of life, better outcomes following subsequent kidney transplantation, delayed need for vascular access (especially in small children), reduced need for erythropoiesis-stimulating agents, and lower risk of blood-borne virus infections and of SARS-CoV-2 infection. PD outcomes have been improving over time but with great variability, driven by individual and system-level inequities and by centre effects; this variation is exacerbated by a lack of standardized outcome definitions. Potential strategies for outcome improvement include enhanced standardization, monitoring and reporting of PD outcomes, and the implementation of continuous quality improvement programmes and of PD-specific interventions, such as incremental PD, the use of biocompatible PD solutions and remote PD monitoring.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Peritoneal Dialysis
/
COVID-19
/
Kidney Failure, Chronic
Type of study:
Observational study
/
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Nat Rev Nephrol
Journal subject:
Nephrology
Year:
2022
Document Type:
Article
Affiliation country:
S41581-022-00623-7
Similar
MEDLINE
...
LILACS
LIS